17e édition du Congrès international sur les thérapies ciblées anti-tumorales (TAT) (notice n° 271748)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01916cam a2200253 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250112080930.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Baldini, Capucine |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | 17e édition du Congrès international sur les thérapies ciblées anti-tumorales (TAT) |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2019.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 26 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | RésuméCette 17e édition du Congrès international sur les thérapies ciblées anti-tumorales (TAT) a été riche de présentations de grande qualité dans le domaine des thérapies innovantes en cancérologie. Le développement des essais de combinaisons et leurs bases rationnelles a, cette année encore, été sujet à débat. Le nombre de ces essais en croissance constante depuis 2016 complexifie le paysage des essais thérapeutiques. Plusieurs succès et échecs ont été mis en évidence au cours de ce congrès qui a fait le point sur les différents résultats de l’année 2018 et les perspectives pour 2019. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | This 17th edition featured many high-quality presentations in the field of innovative cancer therapy. The development of combination trials and their rational basis was, once again, the subject of debate. The constantly growing number of these trials throughout 2016 has rendered the landscape for therapeutic trials more complex. Several successes and failures were highlighted during this congress, which took stock of the various results from 2018 and the outlook for 2019. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | biomarqueurs |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | immunothérapie |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | essais précoces |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | early clinical trials |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | immunotherapy |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | biomarkers |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Aspeslagh, Sandrine |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Innovations & Thérapeutiques en Oncologie | Volume 5 | 3 | 2019-05-01 | p. 177-181 | 2431-3203 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-innovations-et-therapeutiques-en-oncologie-2019-3-page-177?lang=fr">https://shs.cairn.info/revue-innovations-et-therapeutiques-en-oncologie-2019-3-page-177?lang=fr</a> |
Pas d'exemplaire disponible.
Réseaux sociaux